Search research articles
Contact Us
Filters
Showing results (261-270 of 461) with videos related to
Page
of 47
Sort By:
The Journal of Dermatological Treatment
|
May 26, 2024
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Dermatology and Therapy
|
February 2, 2020
Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
Bruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study
Kim A Papp, Melinda Gooderham, Michael Droege, et al.
Lancet (London, England)
|
May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.
The American Journal of Psychiatry
|
November 14, 1997
Multicenter collaborative panic disorder severity scale
M K Shear, T A Brown, D H Barlow, et al.
Journal of Psychosomatic Research
|
March 4, 1998
Hemodynamic response to respiratory challenges in panic disorder
J M Martinez, J D Coplan, S T Browne, et al.
Journal of the American Academy of Dermatology
|
November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Andrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
The American Journal of Psychiatry
|
January 1, 1990
Pharmacotherapy of four men with paruresis
J A Hatterer, J M Gorman, A J Fyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 3, 2013
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A B Kimball, K A Papp, Y Wasfi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 2, 2014
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
K A Papp, K Barber, R Bissonnette, et al.
Page
of 47
Search research articles
Search
Showing results (261-270 of 461) with videos related to
Sort By:
Page
of 47
The Journal of Dermatological Treatment
|
May 26, 2024
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Dermatology and Therapy
|
February 2, 2020
Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
Bruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study
Kim A Papp, Melinda Gooderham, Michael Droege, et al.
Lancet (London, England)
|
May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.
The American Journal of Psychiatry
|
November 14, 1997
Multicenter collaborative panic disorder severity scale
M K Shear, T A Brown, D H Barlow, et al.
Journal of Psychosomatic Research
|
March 4, 1998
Hemodynamic response to respiratory challenges in panic disorder
J M Martinez, J D Coplan, S T Browne, et al.
Journal of the American Academy of Dermatology
|
November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Andrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
The American Journal of Psychiatry
|
January 1, 1990
Pharmacotherapy of four men with paruresis
J A Hatterer, J M Gorman, A J Fyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 3, 2013
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A B Kimball, K A Papp, Y Wasfi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 2, 2014
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
K A Papp, K Barber, R Bissonnette, et al.
Page
of 47